Castle Biosciences targets $345M-$355M 2026 revenue as TissueCypher volumes grow 58% and AdvanceAD-Tx reaches ~650 orders (NASDAQ:CSTL)
Castle BiosciencesCastle Biosciences(US:CSTL) Seeking Alpha·2026-05-07 16:43

新闻内容技术性访问问题 - 提供的文档内容并非新闻正文，而是关于网站访问的技术性提示，要求用户启用Javascript和cookies，或禁用广告拦截器以继续浏览 [1]

Castle Biosciences targets $345M-$355M 2026 revenue as TissueCypher volumes grow 58% and AdvanceAD-Tx reaches ~650 orders (NASDAQ:CSTL) - Reportify